...
首页> 外文期刊>Journal of Medicinal Chemistry >Antitumor agents. 185. Synthesis and biological evaluation of tridemethylthiocolchicine analogues as novel topoisomerase II inhibitors.
【24h】

Antitumor agents. 185. Synthesis and biological evaluation of tridemethylthiocolchicine analogues as novel topoisomerase II inhibitors.

机译:抗肿瘤药。 185.三脱甲基硫代秋水仙碱类似物作为新型拓扑异构酶II抑制剂的合成和生物学评估。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Several 1,2,3-tridemethyldeacetylthiocolchicine derivatives have been synthesized and evaluated for cytotoxic activity against various human tumor cell lines and for their inhibitory effects on DNA topoisomerases in vitro. Exhaustive demethylation of thiocolchicine analogues completely changes their biological profiles. Instead of displaying antitubulin activity, most target compounds inhibited topoisomerase II activity. Only compounds with a larger side chain, such as 15a, 23a, and 24a, did not interfere with topoisomerase II enzymatic functions. The cytotoxicity of target compounds was reduced by 3 orders of magnitude compared to that of colchicine in most cell lines. The hydrophilicity of phenolic compounds might prevent drug passage through the cell plasma membrane and, thus, be responsible for the relatively weak cytotoxicity. To test this hypothesis, 27-30 were prepared from 16a by protecting all hydroxy groups with esters with an aim to facilitate drug transportation. In vitro cytotoxicity assays indicated that 27 was more potent than its parent compound in all tested tumor cell lines and showed tissue selective cytotoxicity with a significant inhibitory effect against KB cells (IC50 = 2.7 microg/mL). Therefore, we propose that 27 acts as a prodrug, liberating 16a to exert its antitopoisomerase activity and, finally, to cause cell death.
机译:几种1,2,3-tridemethyldeacetylthiocolchicine衍生物已合成和评估针对各种人类肿瘤细胞系的细胞毒性活性及其体外对DNA拓扑异构酶的抑制作用。硫代秋水仙碱类似物的穷举脱甲基作用完全改变了它们的生物学特性。大多数目标化合物没有显示抗微管蛋白活性,而是抑制了拓扑异构酶II活性。只有具有较大侧链的化合物(例如15a,23a和24a)才不会干扰拓扑异构酶II的酶功能。与秋水仙碱相比,大多数细胞系中目标化合物的细胞毒性降低了3个数量级。酚类化合物的亲水性可能会阻止药物通过细胞质膜,从而导致相对较弱的细胞毒性。为了检验该假设,通过用酯保护所有羟基,从16a制备27-30,目的是促进药物运输。体外细胞毒性试验表明,在所有测试的肿瘤细胞系中,27种均比其母体化合物更有效,并显示出组织选择性的细胞毒性,对KB细胞具有明显的抑制作用(IC50 = 2.7 microg / mL)。因此,我们建议27用作前药,释放16a以发挥其抗拓扑异构酶活性,并最终导致细胞死亡。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号